Kymera Therapeutics (KYMR) Gains from Investment Securities (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Gains from Investment Securities data on file, last reported at $33.3 million in Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $33.3 million, up 37740.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.7 million (up 7550.0% YoY), and the FY2025 annual result was $9.0 million, changed N/A from the prior year.
• Gains from Investment Securities advanced to $33.3 million in Q1 2026 per KYMR's latest filing, from -$16.0 million in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $33.3 million in Q1 2026 and troughed at -$49.7 million in Q4 2023.
• A 5-year average of -$2.3 million and a median of $276902.0 in 2022 frame the typical range for Gains from Investment Securities.
• The sharpest annual moves came in 2025 and 2026: Gains from Investment Securities sank 98.71% in 2025, then surged 37740.91% in 2026.
• A 5-year view of Gains from Investment Securities shows it stood at $283328.0 in 2022, then slumped by 17656.33% to -$49.7 million in 2023, then jumped by 61.47% to -$19.2 million in 2024, then increased by 16.53% to -$16.0 million in 2025, then jumped by 308.12% to $33.3 million in 2026.
• Business Quant data shows KYMR's Gains from Investment Securities at $33.3 million in Q1 2026, -$16.0 million in Q4 2025, and $8.6 million in Q3 2025.